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NOTUM is a carboxylesterase that has been shown to act by mediating the O-depalmitoleoylation of Wnt
proteins resulting in suppression of Wnt signaling. Here, we describe the development of NOTUM inhibitors
that restore Wnt signaling for use in in vitro disease models where NOTUM over activity is an underlying
cause. A crystallographic fragment screen with NOTUM identified 2-phenoxyacetamide 3 as binding in the
palmitoleate pocket with modest inhibition activity (IC50 33 μM). Optimization of hit 3 by SAR studies
guided by SBDD identified indazole 38 (IC50 0.032 μM) and isoquinoline 45 (IC50 0.085 μM) as potent in-
hibitors of NOTUM. The binding of 45 to NOTUM was rationalized through an X-ray co-crystal structure
determination which showed a flipped binding orientation compared to 3. However, it was not possible to
combine NOTUM inhibition activity with metabolic stability as the majority of the compounds tested were
rapidly metabolized in an NADPH-independent manner.
Members of the Wnt family are secreted signaling proteins
that play key roles in adult stem cell biology as well as in
embryonic development.1 Wnts initiate signaling by binding
to cell surface receptors and two main pathways have been
identified downstream of Wnts: the so-called ‘canonical’ and
‘planar cell polarity’ pathways. These pathways are triggered
by the binding of Wnt to a member of the Frizzled family of
cell surface receptors and, for the canonical pathway, a mem-
ber of the LDL-receptor-related protein (LRP) family of cell
surface receptors (typically LRP5 or LRP6). This binding elicits
an intracellular signaling cascade that results in both bio-
chemical and transcriptional changes within the cell, with the
canonical pathway involving the accumulation and transloca-
tion of β-catenin. Both pathways are tightly regulated by a so-
phisticated network of modulators and feedbacks including
secreted inhibitory Dickkopf (DKK) proteins2 and post trans-
lational modifications (PTM).3,4
Conversely, dysregulation of Wnt signaling is frequently
associated with growth-related pathologies and cancers,5 par-
ticularly those of tissues for which Wnts normally stimulate
self-renewal and repair. Wnt signaling is also implicated to
have a role in neurodegenerative diseases such as Alzheimer's
disease (AD). Cognitive impairments, characteristic of AD,
correlate closely with the loss of synapses and current knowl-
edge suggests that excess amyloid-β (Aβ) causes synapse
dysfunction by impairing synapse maintenance, at least in
part, through causing dysfunction of Wnt signaling.6,7
Compromised Wnt signaling may also be associated with AD
through loss of blood–brain barrier (BBB) integrity8 and Aβ
generation through β-secretase (BACE1) expression.9
O-Palmitoleoylation of a conserved serine residue in Wnt
proteins is a key PTM required for efficient binding of Wnt
proteins to Frizzled receptors, a requirement for signal
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transduction.10 A carboxylesterase NOTUM was previously
shown to antagonize Wnt signaling pathways.11 More re-
cently, NOTUM has been shown to act by mediating the
depalmitoleoylation of Wnt proteins resulting in suppression
of Wnt signaling.12,13 It follows that inhibition of NOTUM
could restore Wnt signaling with potential benefit in disease
where Wnt deficiency is an underlying cause.
There are only a few reports of NOTUM inhibitors with
compounds falling into two main categories (Scheme 1).
Thienopyrimidine LP-922056 (1) is a potent, orally active in-
hibitor of NOTUM that has shown NOTUM to be a potential
drug target for stimulating bone formation and treating oste-
oporosis.14 However, although 1 demonstrates low clearance
and good bioavailability, the structure contains an essential
carboxylic acid and acids tend to have low passive brain
penetration;15–18 in fact, it is an accepted strategy to add a
carboxylic acid group to minimize brain penetration of drugs
for peripheral targets.19 N-Hydroxyhydantoin carbamates are
potent and selective irreversible inhibitors of NOTUM discov-
ered by activity-based protein profiling (ABPP).20 An opti-
mized inhibitor ABC99 (2) preserves Wnt-mediated cell sig-
naling in the presence of NOTUM and was converted to a
clickable ABPP probe for visualizing NOTUM in biological
systems. Due to their reactive mechanism of action forming
covalent adducts with NOTUM Ser232, it is unlikely that
these compounds will be suitable for in vivo studies. Hence,
our objective was to discover potent small molecule inhibi-
tors of NOTUM suitable for exploring the regulation of Wnt
signaling in the central nervous system (CNS) and modula-
tion of AD phenotypes.
In order to identify new small molecule inhibitors of
NOTUM, a crystallographic fragment screen was performed
using the XChem platform at Diamond Light Source. Crystals
of C-terminal his-tagged NOTUM(Ser81-Thr451 Cys330Ser)
were soaked with the DSI-Poised library (XChem, 768 frag-
ments).21 Crystal structures of NOTUM show a distinctive
pocket that accommodates the palmitoleate group (Fig. 1A).12
Fragments observed to bind in the palmitoleate pocket were
all re-synthesized as solid samples to establish structure and
purity. Inhibition of NOTUM carboxylesterase activity of these
hits was measured in a cell-free biochemical assay. In brief,
test compounds (dispensed to give 10 point concentration–
response-curves) were incubated with NOTUM(81-451
Cys330Ser) and trisodium 8-octanoyloxypyrene-1,3,6-
trisulfonate (OPTS) as the substrate for 1 h, and fluorescence
recorded; an inhibitor of NOTUM would suppress fluores-
cence by binding to NOTUM and preventing hydrolysis of
OPTS (ESI,‡ Fig. S1).14,22
One of the preferred hits from this set was
2-(2-methylphenoxy)-N-(pyridine-3-yl)acetamide (3) (IC50 33 ±
4.7 μM) which was selected for further investigation for sev-
eral reasons: (1) excellent “hit-like” properties (mw 242; clog
P 1.7; TPSA 51; LE = 0.35; LLE = 2.8) with no obvious reactive
groups; (2) chemically enabled to selectively functionalize
each position to explore structure activity relationships (SAR);
(3) successful co-crystal structure with NOTUM to support a
structure based drug design (SBDD) program; and (4) struc-
tural features and physicochemical properties consistent with
CNS drug-like space23 including a favorable ‘CNS
multiparameter optimization’ (CNS MPO) score (CNS MPO =
5.6/6.0).24,25 Analysis of the crystal structure (Fig. 1B) showed
key pi–pi stacking interactions between the pyridine ring and
Trp128 at the outer pocket, and further pi–pi interactions be-
tween the tolyl ring and Phe268/Phe320 within the deeper, li-
pophilic pocket. No hydrogen bonding interactions between
the ligand and the protein were observed, so it was consid-
ered that these pi–pi interactions were crucial for binding, in
addition to general lipophilic interactions, as observed for
the palmitoleate ligand (Fig. 1A). Notably, the orientation of
Trp128 is significantly shifted in our crystal structures com-
pared to previous structures like PDB 4UZQ. This shift shows
a more open form of the binding site. Also in contrast to the
O-palmitoleoyl serine structure, 3 does not interact with the
oxyanion hole of the active site.
Two general synthetic methods were used to prepare new
analogues: either an activated amide coupling reaction be-
tween the aminoheterocycle and the 2-phenoxyacetic acid;
or a nucleophilic substitution reaction between the
2-chloroacetamide and the relevant phenoxide (Scheme 1;
see, ESI‡). Inhibition of NOTUM carboxylesterase activity was
Scheme 1 Chemical structures of LP-922056 (1), ABC99 (2) and initial fragment hit 3. General scheme for the synthesis of 2-phenoxyacetamides
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routinely measured in an OPTS biochemical assay as de-
scribed above. Selected compounds were then screened for
NOTUM occupancy in a FP-biotin competition assay26 and/or
inhibition of NOTUM activity in a Wnt/β-catenin signaling
pathway TCF/LEF reporter (luciferase) HEK293 cell line with
exogenous Wnt3a and NOTUM.14,22 Compounds were also
screened for aqueous solubility, transit performance in
MDCK-mdr1 cell lines for permeability, and metabolic stabil-
ity in human and mouse liver microsomes (HLM and MLM
resp.) as a measure of clearance.
The SARs were directed at exploring four principle areas
of the original hit 3: the 2-heteroatom linker (4–7), substitu-
ents on the phenoxy ring (8–18), the acetamide backbone (19,
20) (Table 1), and the amide group (21–53) (Table 2). Further-
more, target compounds were designed to have molecular
and physicochemical properties consistent with CNS drug-
like space. It is generally accepted that CNS drugs tend to oc-
cupy a restricted property space compared to general orally
available drugs,23 and extensive efforts have been made to de-
fine attributes that are desirable for molecules to have good
brain exposure. One such model is the CNS MPO score24,25
which we routinely used in our compound design. A second
useful design metric was lipophilic ligand efficiency
(LLE)27,28 used to track improvements in NOTUM activity
against lipophilicity (clogP) of the inhibitors. The
palmitoleate pocket of NOTUM is a very lipophilic environ-
ment and we were keen to avoid gains in activity simply
through increased compound lipophilicity.
Initial studies suggested that replacing the O-atom linker
was not an effective strategy for increasing activity, with po-
tency decreasing from O > NH > S > CH2 (3–6) (Table 1).
The preference for an O-linker was believed to be due to a fa-
vorable internal H-bond with the amide NH holding the mol-
ecule in a low energy conformation that closely mimicked the
NOTUM binding conformation. The NMe linker 7 was similar
in potency for this matched pair (3 vs. 7) although this did
not prove to be a general trend, and so the O-linker was
retained for the next phase of SAR. N-Methylation of the am-
ide group (19) or the 2-phenoxy propanamide backbone (20)
was tolerated but offered no advantage (Table 1).
Guided by the NOTUM-3 crystal structure, a concise inves-
tigation of SAR of the phenoxy ring indicated the original
2-methyl group in 3 was preferred with a beneficial 2-fold in-
crease in potency only achieved by direct replacement with a
2-chlorine atom 13 (Table 1). Moving the Cl atom or Me
group to the 3-, 4-positions gave a significant decrease in po-
tency (14, 15, 16) and was not pursued further at this point.
These results were consistent with the structural information
showing minimal space to accommodate any group larger
than H- or F-atom (17) in these positions. The symmetrical
2,6-diMe phenoxy ether 18 was tolerated but offered no ad-
vantage over a single 2-Me substituent. From this limited set,
most groups were detrimental, or offered little advantage,
compared to having no substituent (8; R = H) with a prefer-
ence for small lipophilic groups at the 2-position of the ring
such as 2-Me, 2-Cl and 2-CF3.
The next phase of SAR was to explore the N-acetamide
substituent with a variety of heterocycles (Table 2). Although
swapping the 3-Py group for the Ph (21) gave a boost in activ-
ity, this was at a significant penalty in added lipophilicity
Fig. 1 X-ray crystal structures of ligands bound to NOTUM. (A) O-Palmitoleoyl serine (orange) (S232A mutant NOTUM), PDB ID: 4UZQ; (B)
fragment hit 3 (green) with key pi–pi stacking interactions between the ligand and Trp128 and Phe268 indicated, PDB ID: 6R8P; (C) benzotriazole
39 (blue) showing a similar binding mode to 3, but with flipping of Trp128, PDB ID: 6R8Q; (D) isoquinoline 45 (yellow) demonstrates a
reorientation of the phenoxy and amide groups but with key pi–pi stacking interactions maintained, PDB ID: 6R8R. Ligands are shown as sticks,
and protein represented as ribbons with key amino acids shown as lines. Key pi–pi stacking interactions are shown between the ligands and the
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(clogP 2.9, LLE = 2.8), and pyrazine 22 proved to be a more
efficient inhibitor (clog P 0.8, LLE = 4.2). Interestingly, the
3-(aminomethyl)pyridine amide 25 showed a decrease in po-
tency from 3 suggesting that the introduction of the methy-
lene linker disrupted the positioning of the ligand. The most
significant increase in activity was achieved with benzo-fused
heterocycles such as 26 and 27. These results prompted a
more systematic investigation of both 6,5- and 6,6-
heterocycles.
Fused 6,5-ring systems were well tolerated, with a range of
indoles (28, 29), benzimidazoles (30, 31), indazoles (32–38)
and benzotriazoles (39–41) having NOTUM inhibition <1 μM
(Table 2). With good activity now achieved within this series,
indazole 34 (IC50 0.27 ± 0.06 μM) (clogP 3.1; LLE 3.6; CNS
MPO 5.6) was selected as a representative early lead for
in vitro ADME profiling. Indazole 34 had low aqueous ther-
modynamic solubility (2 μg mL−1) and moderate cell perme-
ability as measured by transit performance in the MDCK-
mdr1 cell line with no evidence of P-gp mediated efflux (AB/
BA Papp 5.1/6.6 × 10
6 cm s−1). However, 34 had very poor met-
abolic stability in both HLM and MLM and was found to be
rapidly degraded in a NADPH-independent manner (Table 3).
Hydrolytic stability of 34 was tested in three buffer systems
(pH 4, 7.4, 10) at multiple time points up to 18 h and only
parent was detected by UPLC-MS confirming degradation of
34 was not caused by simple hydrolysis. These results
highlighted the need to further improve NOTUM inhibition
activity whilst simultaneously developing compounds with
good metabolic stability. Hence the microsomal stability as-
say became a priority secondary screen (vide infra).
Further investigation of SAR within the indazole series
showed activity was increased by addition of a larger alkyl
group (Me, Et, iPr) on the N1 or N2 position (35 vs. 37 vs. 38).
Particularly noteworthy is the 2-isopropylindazole 38 (IC50
0.032 ± 0.004 μM) (clogP 4.0; LLE 3.5; CNS MPO 5.1) which
was the most potent NOTUM inhibitor from this 6,5-series.
Benzotriazoles (39–41) were well tolerated with the SAR of the
N1-Me (40) and N2-Me (41) derivatives tracking their counter-
parts in the indazole series (e.g. 32 vs. 35 vs. 41). The
unsubstituted benzotriazole 39 (IC50 0.12 ± 0.04 μM) (clogP
2.8; LLE 4.2; CNS MPO 5.0) offered a slight advantage and
again showed that a free N1-H could be accommodated as
seen previously with indole 26. However, both 38 and 39 were
also rapidly degraded in HLM and MLM in a NADPH-
independent manner.
Fused 6,6-ring systems showed more variation in their
NOTUM inhibition activities with the position of the N atom(s)
critical for achieving good activity (Table 2). A systematic mi-
gration of a single N atom around each available position of
the heterocycle (42–48) showed a preference for the N atom
in the distal ring with a clear advantage for the 6-isoquinoline
isomer 45 (IC50 0.085 ± 0.011 μM) (clogP 3.0; LLE 4.1; CNS
MPO 5.6). Multiple N atoms were accommodated in the distal
ring of the 6,6-rings as shown with quinazoline 49 but was
still inferior to 45.
With good NOTUM inhibition activity achieved across a
range of amides, preferred compounds (IC50 < 0.50 μM) were
submitted for NOTUM X-ray co-crystallography studies to eluci-
date their binding modes. Structures of benzotriazole 39
(Fig. 1C) and isoquinoline 45 (Fig. 1D) were solved and showed
that, while having similar potencies, they differed in their
adopted binding conformations. Both compounds formed pi–
pi stacking interactions with Trp128 through their heterocyclic
rings but there was a distinct difference in the orientation of
their phenoxyacetamide backbones. Benzotriazole 39 adopted a
similar orientation as the pyridinyl fragment 3 (Fig. 1B). In con-
trast, isoquinoline 45 showed a 180° rotation around the amide
bond with the carbonyl oxygen now pointing away from the
oxyanion hole and the methyl group of the tolyl group occupy-
ing the opposite side of the lipophilic pocket.
An overlay of the crystal structures of 3 and 45 showed
that the phenoxy ring of 45 was shifted slightly (ca. 1.28 Å) to-
wards the front of the binding pocket, suggesting the possi-
bility of additional space for further modification to this ring.
Therefore, substitution on the phenoxy ring was revisited in
the 45 series in an attempt to achieve optimal occupancy of
the lipophilic pocket and increase potency. However, once
again, only a 2-Cl group 50 (IC50 0.069 ± 0.011 μM) (clogP
3.3; LLE 3.9; CNS MPO 5.5) was accommodated with the
3-Me 51 and 3-Cl 52 giving a significant decrease in potency,
Table 1 Inhibition of NOTUM activity. SAR of the heteroatom linker, the
phenoxy ring and the acetamide
# X R IC50
a (μM)
3 O 2-Me 33
4 NH 2-Me 60
5 S 2-Me 110
6 CH2 2-Me 140
7 NMe 2-Me 23
8 O H 150
9 O 2-F 290
10 O 2-OMe 170
11 O 2-CN 120
12 O 2-CF3 37
13 O 2-Cl 14
14 O 3-Cl 310
15 O 3-Me 37% I @ 100 μM
16 O 4-Me 20% I @ 100 μM
17 O 2-Me;4-F 20
18 O 2-Me;6-Me 44
19 — — 180
20 — — 100
a Values are geometric means of n = 2–8 experiments quoted to 2 s.f.
Screening data only passed the quality control criteria if the
screening plates demonstrated a Z′ > 0.5 and the NOTUM inhibition
activity of the positive control was within acceptable limits (IC50 0.6–
1.1 nM). Differences of <2-fold should not be considered significant.
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Table 2 Inhibition of NOTUM activity. SAR of the amide heterocycles
# R IC50
a (μM) # R IC50
a (μM)
3 33 21 1.6
22 9.4 23 3.6
24 72 25 100
26 0.21 27 0.68
28 0.33 29 0.24
30 0.52 31 0.98
32 0.36 33 0.27
34 0.27 35 0.28
36 0.20 37 0.068
38 0.032 39 0.12
40 0.44 41 0.27
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although still superior to the direct analogues in the
3-pyridinyl series (14 and 15). Isoquinoline amides 45 and 50
were screened in liver microsomes and also showed rapid
degradation in a NADPH-independent manner.
Representative inhibitors were tested in a NOTUM occu-
pancy assay using FP-biotin, a serine hydrolase activity-based
probe, whereby labelling of NOTUM with FP-biotin can be
blocked by an inhibitor occupying the active site of NOTUM
(Fig. 2A). All inhibitors showed some ability to prevent label-
ling by FP-biotin, confirming they competitively bind to
NOTUM, albeit with modest potency compared to 1, and the
rank order of binding tracks with NOTUM IC50 activity in the
OPTS assay.
Preferred inhibitors were then screened in the cell-based
TCF/LEF reporter gene (Luciferase) assay to assess their abil-
ity to restore Wnt/β-catenin signaling when activated by exog-
enous Wnt3a (100 ng mL−1) in the presence of NOTUM (500
ng mL−1) (Fig. 2B). Assay validation studies with a training
set of NOTUM inhibitors showed that nanomolar activity in
the OPTS assay (IC50 < 1 μM) was required to show activity
in the cell assay; these findings are consistent with previous
reports.14,22 Compound 1 showed an effective activation of
Table 2 (continued)
# R IC50
a (μM) # R IC50
a (μM)
44 1.2 45 0.085
46 0.97 47 0.43
48 15 49 0.67
50 — 0.069 51 — 19
52 — 5.2 53 — 5.7
54 — 7.9
a Values are geometric means of n = 2–8 experiments quoted to 2 s.f. Screening data only passed the quality control criteria if the screening
plates demonstrated a Z′ > 0.5 and the NOTUM inhibition activity of the positive control was within acceptable limits (IC50 0.6–1.1 nM).
Differences of <2-fold should not be considered significant. See also ESI Table S1 for s.e.m.
Table 3 In vitro microsomal stability data for selected compounds
# NOTUM IC50 (μM) HLM (t1/2 min) MLM (t1/2 min) clogP
3 33 — 1.1a 1.7
22 9.4 — Not detecteda 0.8
34 0.27 11.6a Not detecteda 3.1
38 0.032 5.1a 5.7a 4.0
39 0.12 — 1.8a 2.8
45 0.085 12.1a 11.0a 3.0
50 0.069 — 3.3a 3.3
53 5.7 — 5.2a 3.1
54 7.9 — Not detecteda 3.5
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Wnt signaling (EC50 0.138 ± 0.053 μM; n = 4) in this model
system through inhibition of NOTUM (ESI,‡ Table S2). Com-
pound 37 also showed activation of Wnt signaling via inhibi-
tion of NOTUM (EC50 0.386 ± 0.199 μM; n = 4). Compound 38
demonstrated 60% inhibition of NOTUM at 3 μM (estimated
EC50 0.934 ± 0.657 μM; n = 4), whilst 45 and 49 showed 20%
and 38% inhibition at 10 μM respectively. More stringent
EC50 determination was precluded by bell shaped dose re-
sponse curves for the compounds when tested at concentra-
tions > 10 μM. In contrast, 27 and 35 demonstrated a supra-
maximal response consistent with dual activity in this assay,
preventing accurate EC50 determination. These compounds
not only inhibit NOTUM as shown by the Wnt3a-mediated ac-
tivation of the reporter system but also acts as stabilizers of
the luciferase enzyme giving the supramaximal response.29
This luciferase activity is consistent with similar chemical
structures to 3 that have been reported to be inhibitors of lu-
ciferase in the PubChem database.30
Throughout the course of analogue preparation, preferred
examples were assessed for microsomal stability (Table 3).
However, the majority of the compounds tested were rapidly
metabolized in an NADPH-independent manner with t1/2 <
12.5 min. One approach to mitigate this issue was to intro-
duce a NMe linker as a direct replacement for the O linker
with indazole 53 (cf. 34) but this led to a 25-fold decrease in
activity and had no effect on alleviating the NADPH-
independent metabolism. When an isolipophilic non-
aromatic amide was profiled in MLM, tetrahydroisoquinoline
54 was also found to have rapid degradation in a NADPH-
independent manner. Even revisiting some of the more polar
analogues such as 3 and 22 in MLM suffered a similar out-
come. Rapid NADPH-independent metabolism of structurally
related 2-phenoxypropanamides has recently been reported
suggesting a common metabolic liability associated with this
type of scaffold.31 Hence, in light of this work, we recom-
mend assessing the stability of N-aryl 2-phenoxyacetamide
scaffolds to NADPH-independent metabolism in liver micro-
somes early in the drug discovery process.
In summary, a crystallographic fragment screen with
carboxylesterase NOTUM identified 2-phenoxyacetamide 3 as
binding in the palmitoleate pocket with modest inhibition ac-
tivity. Optimization of hit 3 by SAR studies guided by SBDD
identified indazole 38 and isoquinoline 45 as potent inhibitors
of NOTUM with properties entirely consistent with CNS drug
space. Through direct inhibition of NOTUM, 38 and 45 may
prove to be valuable chemical tools for use in in vitro disease
models where over activity of NOTUM suppressing Wnt signal-
ing is an underlying cause. However, ultimately, it was not
possible to combine NOTUM inhibition activity with metabolic
stability in this series as the majority of the compounds tested
in liver microsomes were rapidly metabolized in an NADPH-
independent manner. These compounds represent a step for-
ward in identifying new chemical matter to study the role of
NOTUM in Wnt signaling, and work is ongoing to identify
compounds suitable for in vivo studies to validate NOTUM as
a target in Wnt signaling related CNS disorders.
Funding Sources
E. Y. J.: Structural analysis was performed by Y. Z., L. V., R. R.
R. and E. Y. J. supported by Cancer Research UK (Programme
Grant C375/A17721) and the Wellcome Trust (PhD Training
Programme 102164/B/13/Z). The Wellcome Trust funds the
Wellcome Centre for Human Genetics, University of Oxford
Fig. 2 (A) NOTUM activity-based occupancy assay was performed with FP-biotin (2 μM) and test compounds (10 μM) for 10 minutes in condi-
tioned media from HEK293S cells stably transfected with a NOTUM lentiviral construct. Relative occupancy was calculated by optical density of
fluorescent band detecting the level of biotinylation of NOTUM using image studio lite 5.2, compared to the control-treated sample which was set
to 1. N = 3 with S.D. statistical significance is calculated using an unpaired t-test with Welch's adjustment (***p ≤ 0.0005, **p ≤ 0.005). UT,
untreated. (B) Percentage activation of the Wnt pathway via inhibition of NOTUM by compounds in the stable TCF-Lef SuperTOPFLASH luciferase
reporter HEK293T cell line. Cells were treated in 8 point concentration response curves from 3 nM to 10 μM for 18 hours. % activation of the TCF/
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